Natriuretic peptides in cardiovascular diseases

Cellular & Molecular Biology Letters

Mariusz Piechota⁴  Anna Jacoń³  Jacek Rysz¹  Maciej Banach² 

[1] 2nd Department of Family Medicine, University Hospital No. 2 in Łódź, Medical University in Łódź, Łódź, Poland$$;Department Cardiology, 1st Chair of Cardiology and Cardiac Surgery, University Hospital No. 3 in Łódź, Medical University in Łódź, Łódź, Poland$$;Department of Health Protection Policy, Medical University of Łódź, Łódź, Poland$$;Department of Anaesthesiology and Intensive Care Unit, Boleslaw Szarecki, University Hospital No. 5 in Łódź, Medical University in Łódź, Łódź, Poland$$

关键词: Atrial natriuretic peptide;    Brain natriuretic peptide;    C-type natriuretic peptide;    Dendroaspis natriuretic peptide;    Urodilatin;    Endothelin-1;   

DOI  :  10.2478/s11658-007-0046-6

学科分类：分子生物学，细胞生物学和基因

来源: Uniwersytet Wroclawski * Wydzial Biotechnologii / University of Wroclaw, Faculty of Biotechnology

【 摘 要 】

The natriuretic peptide family comprises atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), C-type natriuretic peptide (CNP), dendroaspis natriuretic peptide (DNP), and urodilatin. The activities of natriuretic peptides and endothelins are strictly associated with each other. ANP and BNP inhibit endothelin-1 (ET-1) production. ET-1 stimulates natriuretic peptide synthesis. All natriuretic peptides are synthesized from polypeptide precursors. Changes in natriuretic peptides and endothelin release were observed in many cardiovascular diseases: e.g. chronic heart failure, left ventricular dysfunction and coronary artery disease.

【 授权许可】

Unknown